AP Biosciences’s two core licensed assets, IBI302 and AP505, are entering critical negotiation stages. General Manager Ho Cheng-hung stated on the 15th that the company has received "Science and Technology Business" approval and plans to file for an Over-the-Counter (OTC) listing by the end of 2024, targeting a market debut in H1 2025.

• IBI302 (wet AMD & DME): Licensed to Innovent Biologics. Phase 3 clinical trials for wet Age-related Macular Degeneration (wet AMD) are expected to yield primary efficacy and safety data in H1 2026. Global big pharma interest is high, with OBIIS set to receive a share of sub-licensing fees.
• AP505 (PD-L1 x VEGF Bispecific Antibody): Licensed to Tasly Pharmaceutical for Greater China. Phase 1 results showed clinical value, and two Phase 2 trials (including colorectal cancer) launched in early 2025. OBIIS is leading licensing talks for ex-China markets, with over five top-15 global pharma companies inquiring.
• Pipeline Updates: * AP203 (PD-L1 x CD137): Phase 1 (Taiwan) completion targeted for H2 2026.
• AP402 (p95HER2 x CD137): First-in-class; Phase 1 (Australia) completion targeted for Q4 2026.
• AP601 (CD73 x CD137): First patient enrollment expected in early 2026.

Resource: 雙核心藥物將進入關鍵授權節點，圓祥生技年底啟動上櫃申請